Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 2/20 | 0.59 |
| ▸ | IGF1R | P08069 | 12/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | TEK | Q02763 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172054 | 0.85 | IGF1R (0.67) | EPHB4IGF1RKDREGFRINSR | |
| SCHEMBL1172210 | 0.85 | IGF1R (0.61) | IGF1RKDREGFRINSRMET | |
| SCHEMBL1172768 | 0.81 | IGF1R (0.64) | IGF1RKDREGFRINSRMET | |
| SCHEMBL1172280 | 0.81 | IGF1R (0.67) | IGF1RKDREGFRINSRMET | |
| SCHEMBL1116462 | 0.80 | IGF1R (0.79) | EPHB4IGF1RJAK2KDREGFR | |
| SCHEMBL1172205 | 0.79 | JAK2 (0.59) | IGF1RJAK2KDREGFRINSR | |
| SCHEMBL13866467 | 0.78 | PTK2 (0.65) | IGF1RJAK2JAK3KDREGFR | |
| SCHEMBL12865250 | 0.78 | IGF1R (0.66) | EPHB4IGF1RKDREGFRINSR | |
| SCHEMBL1171685 | 0.78 | EPHB4 (0.71) | EPHB4IGF1RJAK2KDREGFR | |
| SCHEMBL6981464 | 0.77 | IGF1R (0.78) | IGF1RKDREGFRINSRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| EP-1981856-A2 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085833-A2 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | EPHB4, EPHB1, EPHB3 | EPHB4 1/4885IGF1R 1124/4885JAK2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.